Abbott Laboratories is a moat-backed medical device maker with strong momentum and a golden cross, but price is within 0.4% of the analyst target, earnings growth is flat and negative news sentiment weighs on the near-term view.
Thesis pillars
- Moat Backed Device Franchise→Stable
- Strong Uptrend Breakout↑Improving
- Target Nearly Reached→Stable
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Nov 1, 2026, based on the 10-K filed Feb 20, 2026
Abbott Laboratories (ABT) Stock Analysis
Healthcare · Medical Devices
Hold if already holding. Not a fresh buy at $115.51, but acceptable to hold if already in. Reasons: Concentration risk — Geographic: international sales (61.0%); Analyst target reached - limited upside remaining.
Abbott Laboratories develops, manufactures, and sells healthcare products across four segments: Established Pharmaceuticals (branded generics sold in emerging markets), Diagnostic Products, Nutritional Products, and Medical Devices including FreeStyle Libre CGM and MitraClip.... Read more
Hold if already holding. Not a fresh buy at $115.51, but acceptable to hold if already in. Reasons: Concentration risk — Geographic: international sales (61.0%); Analyst target reached - limited upside remaining. Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Score 5.4/10, moderate confidence.
Passes 6/8 gates (positive momentum, clean insider activity, news events none recent, earnings proximity 84d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
Recent developments
No fresh coverage since Oct 21, 2026
Recent Developments — Abbott Laboratories
Latest news
- NEWS Abbott Wavers On 'Choppy' Quarter With A Spinoff Looming - Investor's Business Daily — Investor's Business Daily Oct 21, 2026 neutral
- NEWS Abbott Stock Falls After Earnings. It’s Shedding Its Troubled Nutrition Unit. - Barron's — Barron's Oct 21, 2026 negative
- NEWS Abbott Q3: Nutrition Spin-Out, Narrowed Guidance Rocks Stock; For Now, At Least (ABT) - Seeking Alpha — Seeking Alpha Oct 21, 2026 negative
- NEWS What Abbott Laboratories (ABT) Said on Its Q3 Earnings Call - TradingView — TradingView Oct 21, 2026 neutral
- NEWS What Abbott Laboratories (ABT) Said on Its Q3 Earnings Call - Yahoo Finance — Yahoo Finance Oct 21, 2026 neutral
Latest item Oct 21, 2026 · Generated 2026-11-05T11:54:11Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHGeographicinternational sales61%10-K Item 1A: 'Sales outside of the U.S. in 2025 made up approximately 61 percent of Abbott's net sales'
Material Events(8-K, last 90d)
- 2026-04-27Item 5.02LOWKevin Conroy named to Abbott Board of Directors on April 24, 2026. Shareholders also approved 2026 Incentive Stock Program at Annual Meeting, replacing the 2017 Program. Routine board appointment; no officer departure.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $115.51, but acceptable to hold if already in. Reasons: Concentration risk — Geographic: international sales (61.0%); Analyst target reached - limited upside remaining. Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Analyst target $106.67 reached (−7.7%), stop $108.83 (−6.1%), A.R:R -0.5:1. Score 5.4/10, moderate confidence.
Analyst target $106.67 reached (−7.7% from $115.51); no take-profit level is published. Analyst target $106.67 reached (−7.7%), stop $108.83 (−6.1%), A.R:R -0.5:1. Stop-loss: $108.83.
Concentration risk — Geographic: international sales (61.0%); Analyst target reached - limited upside remaining; Weak growth.
Abbott Laboratories trades at a P/E of 42.9 (forward 19.5). TrendMatrix value score: 4.6/10. Verdict: Hold.
33 analysts rate ABT, with a consensus score of 4.1/5. 26 analysts publish price targets averaging $119.
What does Abbott Laboratories do?Abbott Laboratories develops, manufactures, and sells healthcare products across four segments: Established...
Abbott Laboratories develops, manufactures, and sells healthcare products across four segments: Established Pharmaceuticals (branded generics sold in emerging markets), Diagnostic Products, Nutritional Products, and Medical Devices including FreeStyle Libre CGM and MitraClip. Approximately 61% of net sales came from outside the United States in 2025, with roughly 115,000 employees serving customers in more than 160 countries.